Opella, based in France, is a global leader in the consumer healthcare market and its portfolio includes well-known brands such as Allegra, Doliprane, and Dulcolax, catering to over 500 million ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global and fast-moving consumer healthcare company, Sanofi said. Bpifrance is expected to participate as a ...

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer ...

French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

Sanofi would remain a significant shareholder backing Opella in its future growth and path to independence. Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and ...

Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake.

Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company’s consumer health business, Opella, to ...

Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at around 16 billion euros ($17 billion), or 14 times estimated core ...

Paris, October 21, 2024.Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion.

Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake.